Ardea Biosciences — Corporate Update (December 2009)
37 slides from Ardea Biosciences's corporate update, Dec 1, 2009
Slide 1: Company Update December 1, 2009
Company Update December 1, 2009
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results
Slide 3: Status of Development Programs
Status of Development Programs RDEA427 RDEA806 900 Series Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 NNRTI for HIV NNRTI for HIV MEKI for cancer Gout RDEA594 RDEA684 MEKI + sorafenib for cancer RDEA119 Gout Partnered with Bayer RDEA119 3rd Gen NNRTIs 3
Slide 4: Gout/Hyperuricemia
Gout/Hyperuricemia Ardea (Biosciences
Slide 5: Hyperuricemia/Gout - Unmet Medical Need
Hyperuricemia/Gout - Unmet Medical Need Gout is caused by abnormally elevated levels of uric acid (>6.8 mg/dL) Painful and debilitating disease Attacks of severe pain/Inflammation Disfiguring nodules (tophi) Kidney damage (nephropathy) Increasing incidence and severity in U.S. (> 5,000,000 potential
Slide 6: Uric Acid Production and Elimination
Hare, J. M. et al. Circulation 2003;107:1951-1953 Uric Acid Production and Elimination Allopurinol Febuxostat RDEA594 Probenecid Losartan (Cozaar(r)) Benzbromarone* 6 *Benzbromarone is a URAT1 inhibitor approved outside of the US and later withdrawn due to liver toxicity. Pegloticase URAT1
Slide 7: URAT1 Inhibitors Increase the Urinary Excretion of Uric Acid
>99% Reabsorption Excretion ~100% of uric acid is initially filtered through glomerular filtration URAT1 Inhibitors Increase the Urinary Excretion of Uric Acid URAT1 Enomoto; Urat1 identification in Nature May2002 D Levinson & L Sorensen; Renal Handling of Uric Acid Proximal Tubule Benzbromarone RDE
Slide 8: Selective URAT1 Transporter Inhibition: An Important Contribution to the Treatment of Hyperuricemia/Gout
8 Selective URAT1 Transporter Inhibition: An Important Contribution to the Treatment of Hyperuricemia/Gout Inhibition of the URAT1 transporter is a well-validated target for gout Benzbromarone has over 10 million patient-years of treatment experience, with very few side effects, except liver toxicit
Slide 9: Uric Acid-Lowering Was Observed with RDEA806
Uric Acid-Lowering Was Observed with RDEA806 Up to 45% reductions in serum urate (sUA) were observed in healthy volunteers in the 10-day multiple ascending dose study of RDEA806 Uric acid reductions were also observed in all HIV patients in the Phase 2a monotherapy study with RDEA806 A 28-day proof-
Slide 10: RDEA594 Preclinical and Phase 1 Summary
RDEA594 Preclinical and Phase 1 Summary RDEA594 is a selective inhibitor of the URAT1 renal transporter (EC50 = 5-10 ^M) without antiviral activity No interactions with antivirals or other drugs secreted by OAT1 and OAT3 transporters observed in humans or animals Limited metabolism by CYP450 Inhibit
Slide 11: RDEA594 Phase 2a Pilot Pharmacodynamic and Safety Study in Gout Patients
Arm 1:RDEA594 200 mg QD Screening Period Colchicine Treatment Randomize if no gout flare during 2 weeks of colchicine Off drug Off drug Arm 2: Placebo 400 mg QD Off drug Arm 3: Allopurinol 300 mg 5 pts 5 pts 11 pts 7-21 days 1 week 2 weeks total with dose escalation of RDEA594 after Week 1 1 week Po
Slide 12: Phase 2a Cohort Baseline Demographics
Phase 2a Cohort 1 Baseline Demographics Parameter Placebo RDEA594 Allopurinol Age Mean (SD) Mean (SD) 50.2 (9.5) 54.3 (13.7) 43.4 (5.9) (years) Median Median 51 56 43 Min, Max Min, Max 40, 65 27, 72 35, 56 BMI Mean (SD) Mean (SD) 33.4 (4.2) 27.8 (3.1) 31.4 (6.9) (kg/m2) Median Median 32.2 27.7 29.2
Slide 13: Both Active Arms Produced Significant Reductions in sUA
Randomized Drug Washout Period All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers All Randomized Subjects Excluding Overproducers Response defined as < 6.0 mg/dL Placebo % (n/N) RDEA594 % (n/N) Allopurinol %
Slide 14: Allopurinol Results From RDEA594 Phase 2a Inconsistent with Previous Studies
Allopurinol Results From RDEA594 Phase 2a Inconsistent with Previous Studies 14 Allopurinol Arms from Febuxostat Phase 3 Studies Allopurinol Arms from Febuxostat Phase 3 Studies Allopurinol Arms from Febuxostat Phase 3 Studies Allopurinol Arm from RDEA594 Phase 2a Results APEX 28-Week Study FACT 52-
Slide 15: 83% Response in Renally Impaired Patients Observed with RDEA594
83% Response in Renally Impaired Patients Observed with RDEA594 All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with Mild to Moderate Renal Insufficiency (Cockcroft-Gault) All Subjects with
Slide 16: RDEA594 Normalizes Uric Acid Excretion
RDEA594 Normalizes Uric Acid Excretion 16
Slide 17: RDEA594 Normalizes Uric Acid Excretion
RDEA594 Normalizes Uric Acid Excretion Overall results confirm dose selection for Phase 2b Keeping renal excretion of uric acid at normal levels should minimize risk of kidney stones 17
Slide 18: Adverse Events by Treatment Group
Treatment Group Mild Moderate Severe Serious Adverse Event Treatment Group (grade 1) (grade 2) (grade 3) Serious Adverse Event Treatment Group N Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Nu
Slide 19: Undissociated Urinary Uric Acid is the Most Important Risk Factor for Nephrolithiasis
Undissociated Urinary Uric Acid (UUua) is the Most Important Risk Factor for Nephrolithiasis* 19 Patients on uricosurics with UUua<20 mg/dL had same rate of lithiasis as patients on allopurinol * 2009 ACR Philadelphia, Presentation 1499 Risk Factors for Renal Lithiasis During the Treatment with Uric
Slide 20: No Pharmacokinetic Interactions Observed Between RDEA594 and Febuxostat
No Pharmacokinetic Interactions Observed Between RDEA594 and Febuxostat at Steady-State 20 Febuxostat RDEA594
Slide 21: Additive Reduction in sUA Observed with Combination of RDEA594 and Febuxostat
Monotherapy Combination Additive Reduction in sUA Observed with Combination of RDEA594 and Febuxostat Febuxostat 120mg in healthy subjects* *Khosravan, et al. Clin Pharmacokinet 2006; 45 (8): 821-841 21 No safety issues with combination The only clinically relevant laboratory abnormality were two gr
Slide 22: Overall Summary of Safety for RDEA594 Through Phase 2a
Overall Summary of Safety for RDEA594 Through Phase 2a Patients exposed to RDEA594: Healthy subjects and HIV pts (RDEA806) ~360 for up to 14 days Gout patients ~ 40 for up to 28 days Control subjects ~ 88 22 Arm Discontinuations Due to AEs N (%) Serious Adverse Events N (%) Grade 2 or Greater Labora
Slide 23: RDEA594 Phase 2 Program Focuses on Important Commercial Opportunities
RDEA594 Phase 2 Program Focuses on Important Commercial Opportunities Phase 2b monotherapy dose-response, safety and efficacy study (n=140) Supports use in patients who are intolerant to allopurinol, inadequate responders to allopurinol, and first-line treatment (not primary target) Phase 2b allopur
Slide 24: RDEA594 Phase 2b Monotherapy Dose-Response, Safety and Efficacy Study
RDEA594 Phase 2b Monotherapy Dose- Response, Safety and Efficacy Study - Enrolling 21 days 2 weeks 4 weeks 2 weeks Population: gout patients with hyperuricemia (serum uric acid ^8 mg/dL) total of 140 patients in 4 treatment arms Duration: 8 wks: 2-wk run-in, 4-wk treatment, 2-wk follow-up: dose will
Slide 25: RDEA594 Phase 2b Allopurinol Add-On Combination Safety and Efficacy Study
RDEA594 Phase 2b Allopurinol Add-On Combination Safety and Efficacy Study - Enrolling Dose Escalation Based on sUA Lowering with 200 mg RDEA594: 18 patients initially, including 12 patients randomized to RDEA594 and 6 patients randomized to placebo 25 RDEA594 100 mg or placebo plus allopurinol 300 m
Slide 26: RDEA594-204: Renal Impairment in Patients with Gout and Hyperuricemia
RDEA594-204: Renal Impairment in Patients with Gout and Hyperuricemia - Screening Cohort 1A: (6 subjects) 200 mg RDEA594 Subjects must have moderate renal impairment defined as creatinine clearance from (CrCL) ^ 30 mL/min to < 60 mL/min Subjects will receive RDEA594 once daily for 5 days Cohorts 1a
Slide 27: Gout/Hyperuricemia Program Summary
27 There is a large unmet need for new treatments for gout RDEA594, a selective URAT1 transport inhibitor, corrects the physiologic cause of the vast majority of patients with hyperuricemia: uric acid under- excretion Clinical proof-of-concept has been achieved Phase 2a - Cohort 1 supports the dose
Slide 28: HIV
HIV Ardea (Biosciences
Slide 29: RDEA427 Has Superior Resistance Profile to Other NNRTIs
RDEA427 Has Superior Resistance Profile to Other NNRTIs 29
Slide 30: Series of NNRTIs Have Excellent Antiviral Profile
900 Series of NNRTIs Have Excellent Antiviral Profile The 900 series retain potency against a large panel of NNRTI-resistant viruses without the liability of a cyano-vinyl moiety in TMC278 and IDX899 Ardea does not have any payment obligations to Valeant on this series 900 Series 30
Slide 31: Cancer MEK program licensed to Bayer Healthcare
Cancer 31 MEK program licensed to Bayer Healthcare on April 28, 2009 $35 million upfront license fee Payments could total $407 million, excluding royalties Low double-digit royalties on worldwide sales Ardea responsible for completing two dose-finding studies (expected completion 1H10)
Slide 32: The Age of Targeted Cancer Treatments
The Age of Targeted Cancer Treatments Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2) XL518 (Ph 1) RDEA119 (Ph 1/2) RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 32
Slide 33: RDEA119 is Potent, Highly Specific MEK Inhibitor
RDEA119 is Potent, Highly Specific MEK Inhibitor MEK1/2 Enzyme IC50 17-50 nM Cellular pERK EC50 2.5-8.7 nM* >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** *Cell lines: Colo205, A375, A431, HT-29 ** In-house data 1 6 11 16 21 26 31 0 20 40 60 80 100 1 6 11 16 21 26 31 MEK1 & MEK2 MEK
Slide 34: Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines
Synergy between RDEA119 and Sorafenib in Hepatoma Cancer Lines 34
Slide 35: RDEA119 Steady-State Plasma Concentrations in Advanced Cancer Patients
RDEA119 Steady-State Plasma Concentrations in Advanced Cancer Patients 100 mg 60 mg 40 mg 30 mg 20 mg 10 mg 6 mg 4 mg 2 mg Shaded area represents Cmin free drug plasma levels observed in xenograft studies up to 25 mg/kg BID, which produced >100% tumor growth inhibition (TGI) QD Dose 35 Mean RDEA119
Slide 36: Financial Position Summary
Financial Position Summary Statement of Operations (In thousands, except per share data) Nine Months Ended Sept. 30, 2009 Revenue Operating expenses Other expense $ 14,681 38,527 (691) NET LOSS $(24,537) NET LOSS PER SHARE $(1.36) 18.4 million common shares outstanding Expect 2009 year-end cash bala
Slide 37: Near-Term Anticipated Milestones
Near-Term Anticipated Milestones Drug Candidate Event Date Date Gout Gout Gout Gout RDEA594 Phase 2a Start 2Q09 Phase 2a Start 2Q09 ? RDEA594 Phase 2b Start in 7/09 Phase 2b Start in 7/09 ? RDEA594 Phase 2a - Cohort 2 Allopurinol Combo Results Phase 2a - Cohort 2 Allopurinol Combo Results 4Q09 RDEA5